{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:09:54Z","timestamp":1790057394806,"version":"4.0.1"},"reference-count":28,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Endocrine Society Annual Meeting"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"Abstract<\/jats:title>\n \n Context<\/jats:title>\n Thyroid eye disease (TED) negatively affects quality of life. TED occurs predominantly in Graves\u2019 disease (GD). Teprotumumab improves TED but concern for hearing adverse events (AEs) has emerged. Hearing dysfunction is reported in thyroid autoimmune disease but the background prevalence in GD\/TED without teprotumumab remains uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This work aimed to quantify ear-related diagnostic codes\/hearing AEs in GD, TED, and patients receiving teprotumumab by examining medical claims and clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Deidentified claims for ear\/labyrinth-related International Classification of Disorders, Tenth Revision codes (KOMODO) were examined in GD patients without TED, and TED patients without\/with teprotumumab treatment. Hearing AE incidence\/severity was evaluated in teprotumumab clinical trials. Graves\u2019 Ophthalmopathy Quality of Life questionnaire (GO-QOL) scores were compared in teprotumumab TED trial patients without\/with hearing AEs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n GD (469 720), TED (38 566) and teprotumumab-treated (967) patients were identified in the claims database. Ear-related codes (including those not specific for hearing) occurred in 24% GD, 33% TED, and 32% teprotumumab-treated patients. \u201cSensorineural hearing loss bilateral\u201d was most frequent: 7% (32 961\/469 720) GD, 11.1% (4279\/38 566) TED, and 10.8% (104\/967) teprotumumab patients. Before teprotumumab use, 17.1% (165) patients had ear-related codes, while 10.1% (98) had new ear-related codes post treatment.<\/jats:p>\n Eight teprotumumab oncology trials revealed 8.1% (51\/633) had ear\/labyrinth disorders with 2.1% (13) considered study-drug-related and 3.8% (24) hearing impairment\/tinnitus-related AEs with 1.3% (8) considered study-drug-related. Similar rates occurred in TED trials.<\/jats:p>\n GO-QOL improved in teprotumumab-treated patients without\/with hearing AEs. Incidence\/severity was consistent across patients with chronic and acute TED.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n These analyses indicate similar prevalence of hearing claims in patients with GD\/TED alone as following teprotumumab treatment. Future analyses of incremental hearing risk from teprotumumab should use a priori study designs accounting for background hearing dysfunction in patients with GD\/TED.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/clinem\/dgae560","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:09:25Z","timestamp":1723612165000},"page":"811-819","source":"Crossref","is-referenced-by-count":11,"title":["Assessment of Hearing Dysfunction in Patients With Graves\u2019 Disease and Thyroid Eye Disease Without or With Teprotumumab"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-9685","authenticated-orcid":false,"given":"Terry J","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, and Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Holt","sequence":"additional","affiliation":[{"name":"Medical Affairs, Amgen Inc , Thousand Oaks, CA 91320 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhong","family":"Fu","sequence":"additional","affiliation":[{"name":"Medical Affairs, Amgen Inc , Thousand Oaks, CA 91320 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Qashqai","sequence":"additional","affiliation":[{"name":"Medical Affairs, Amgen Inc , Thousand Oaks, CA 91320 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Barretto","sequence":"additional","affiliation":[{"name":"Medical Affairs, Amgen Inc , Thousand Oaks, CA 91320 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Conrad","sequence":"additional","affiliation":[{"name":"Medical Affairs, Amgen Inc , Thousand Oaks, CA 91320 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Brant","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\u2014Head and Neck Surgery, University of Pennsylvania , Philadelphia, PA 19104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"16","key":"2025021815502419900_dgae560-B1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2025021815502419900_dgae560-B2","doi-asserted-by":"crossref","first-page":"e220189","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"2","key":"2025021815502419900_dgae560-B3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamaophthalmol.2022.3225","article-title":"Utility assessment of moderate to severe thyroid eye disease health states","volume":"141","author":"Smith","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"2025021815502419900_dgae560-B4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"2025021815502419900_dgae560-B5","doi-asserted-by":"crossref","first-page":"653627","DOI":"10.3389\/fendo.2021.653627","article-title":"Insulin-Like growth factor pathway and the thyroid","volume":"12","author":"Smith","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2025021815502419900_dgae560-B6","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"issue":"18","key":"2025021815502419900_dgae560-B7","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025021815502419900_dgae560-B8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2025021815502419900_dgae560-B9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in Longer-duration thyroid disease and Re-treatment, OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"6","key":"2025021815502419900_dgae560-B10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomized, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2025021815502419900_dgae560-B11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41574-024-00995-9","article-title":"Hearing abnormalities in patients treated with teprotumumab","volume":"20","author":"Brant","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2025021815502419900_dgae560-B12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/00034894211042740","article-title":"Ototoxicity and teprotumumab","volume":"131","author":"Highland","year":"2022","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"2","key":"2025021815502419900_dgae560-B13","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1097\/MAO.0000000000003428","article-title":"Sensorineural hearing loss after teprotumumab therapy for thyroid eye disease: a case report","volume":"43","author":"Ding","year":"2022","journal-title":"Otol Neurotol"},{"key":"2025021815502419900_dgae560-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2025021815502419900_dgae560-B15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12020-011-9515-9","article-title":"Evaluation of hearing loss in patients with graves\u2019 disease","volume":"41","author":"Berker","year":"2012","journal-title":"Endocrine"},{"key":"2025021815502419900_dgae560-B16","first-page":"1","article-title":"Investigating the possible audiological effects of hypothyroidism","volume":"4","author":"Mahafzah","year":"2018","journal-title":"J Phonet Audiol"},{"issue":"3","key":"2025021815502419900_dgae560-B17","first-page":"109","article-title":"The prevalence of hearing loss in patients with autoimmune thyroid disease: a prospective study","volume":"52","author":"Mahafzah","year":"2018","journal-title":"J Med J"},{"issue":"8","key":"2025021815502419900_dgae560-B18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.str.2022.05.007","article-title":"How insulin-like growth factor I binds to a hybrid insulin receptor type 1 insulin-like growth factor receptor","volume":"30","author":"Xu","year":"2022","journal-title":"Structure"},{"issue":"1","key":"2025021815502419900_dgae560-B19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/thy.2023.0466","article-title":"A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease","volume":"34","author":"Douglas","year":"2024","journal-title":"Thyroid"},{"key":"2025021815502419900_dgae560-B20","author":"\u00a92024 Komodo Health, Inc"},{"key":"2025021815502419900_dgae560-B21","doi-asserted-by":"publisher","DOI":"10.17632\/tgj5v33xkk.1"},{"issue":"3","key":"2025021815502419900_dgae560-B22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025021815502419900_dgae560-B23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in thyroid eye disease patients with long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025021815502419900_dgae560-B24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"European Group on Graves\u2019 Orbitopathy (EUGOGO)","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025021815502419900_dgae560-B25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"2025021815502419900_dgae560-B26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/clinem\/dgae417","article-title":"Postmarketing safety concerns of teprotumumab: a real-world pharmacovigilance assessment","volume":"110","author":"Huang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815502419900_dgae560-B27","author":"\u201cFDA Adverse Event Reporting System (FAERS) Public Dashboard"},{"key":"2025021815502419900_dgae560-B28","author":"Amgen Inc"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae560\/59003863\/dgae560.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae560\/59003863\/dgae560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae560\/59003863\/dgae560.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:10:49Z","timestamp":1739895049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/3\/811\/7733237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,14]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae560","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,8,14]]}}}